← Back to Clinical Trials
Recruiting NCT06641297

NCT06641297 White Matter Plasticity in Schizophrenia

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06641297
Status Recruiting
Phase
Sponsor University of Maryland, Baltimore
Condition Schizophrenia Disorders
Study Type INTERVENTIONAL
Enrollment 36 participants
Start Date 2025-01-02
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 15 Years
Max Age 45 Years
Study Type INTERVENTIONAL
Interventions
Music video game

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 36 participants in total. It began in 2025-01-02 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Schizophrenia spectrum disorders are associated with impairment in the microstructure of white matter, the key brain tissue responsible for fast communication between different brain regions necessary for any complex task. This white matter impairment is linked to problems with cognition in schizophrenia, especially slower processing speed. This project aims to study the potential for correcting white matter deficits in schizophrenia by examining mechanisms underlying white matter structure changes in response to training on playing a mock musical instrument.

Eligibility Criteria

Inclusion Criteria: * Diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, or psychosis NOS * age 15-45 * able to provide informed consent Exclusion Criteria: * contraindications to MRI (metal implants, claustrophobia) * medical condition that limits use of hands (ie, arthritis) * Active or recent (within 6 months) substance use disorder other than nicotine

Contact & Investigator

Central Contact

Joshua J Chiappelli, MD

✉ jchiappe@som.umaryland.edu

📞 4104026827

Frequently Asked Questions

Who can join the NCT06641297 clinical trial?

This trial is open to participants of all sexes, aged 15 Years or older, up to 45 Years, studying Schizophrenia Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06641297 currently recruiting?

Yes, NCT06641297 is actively recruiting participants. Contact the research team at jchiappe@som.umaryland.edu for enrollment information.

Where is the NCT06641297 trial being conducted?

This trial is being conducted at Catonsville, United States, Catonsville, United States.

Who is sponsoring the NCT06641297 clinical trial?

NCT06641297 is sponsored by University of Maryland, Baltimore. The trial plans to enroll 36 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology